NeoGenomics Reports 11.2% Revenue Growth to $201.7 Million in Q2 2026

NeoGenomics, Inc. reported a notable increase in financial performance for the second quarter of 2026, with net revenue reaching $201.7 million, an 11.2% increase from $181.3 million in the same period of 2025. For the first half of 2026, revenue totaled $388.3 million, up from $349.4 million year-over-year. The company attributed this growth primarily to an increase in test volume and higher average unit prices, despite a decline in non-clinical revenue due to macro trends in the pharmaceutical industry.

The company's gross profit for the second quarter was $91.9 million, reflecting an 18.9% increase compared to $77.3 million in the prior year, resulting in a gross profit margin of 45.6%, up from 42.6%. Operating expenses decreased significantly, with general and administrative costs falling to $63.6 million from $71.7 million, largely due to reduced legal and professional fees. This led to a loss from operations of $9.8 million, a substantial improvement from a loss of $47.6 million in the same quarter of 2025. The company reported a net income of $2.2 million for the quarter, compared to a net loss of $45.1 million in the prior year.

In terms of strategic developments, NeoGenomics completed the acquisition of Pathline, LLC in April 2025, enhancing its capabilities in the Northeastern United States. The company also repurchased 2.4 million shares of its common stock for $25 million, funded by proceeds from the issuance of $316.3 million in convertible senior notes due 2032. This strategic move is expected to reduce potential dilution of shares and strengthen the company's capital structure.

Operationally, NeoGenomics has expanded its testing capabilities, with a focus on oncology diagnostics. The company operates multiple laboratories across the U.S. and the U.K., and it has seen increased adoption of its molecular testing services, particularly in next-generation sequencing (NGS). As of June 30, 2026, NeoGenomics reported a total employee headcount of 1,200, reflecting its commitment to scaling operations to meet growing demand.

Looking ahead, NeoGenomics anticipates continued growth driven by its focus on precision oncology and expanding its market presence in community oncology. The company plans to invest in research and development, particularly in its therapy selection and molecular residual disease (MRD) testing portfolios. Management remains optimistic about achieving sustainable growth while navigating potential regulatory changes and market conditions that could impact its operations.